MA53002A - Nouveaux composés de pyridine et de pyrazine en tant qu'inhibiteurs du récepteur cannabinoïde 2 - Google Patents

Nouveaux composés de pyridine et de pyrazine en tant qu'inhibiteurs du récepteur cannabinoïde 2

Info

Publication number
MA53002A
MA53002A MA053002A MA53002A MA53002A MA 53002 A MA53002 A MA 53002A MA 053002 A MA053002 A MA 053002A MA 53002 A MA53002 A MA 53002A MA 53002 A MA53002 A MA 53002A
Authority
MA
Morocco
Prior art keywords
cannabinoid
pyrazine
pyridine
new compounds
receptor inhibitors
Prior art date
Application number
MA053002A
Other languages
English (en)
Inventor
Simon M Ametamey
Luca Gobbi
Uwe Grether
Julian Kretz
Original Assignee
Eth Zuerich
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eth Zuerich, Hoffmann La Roche filed Critical Eth Zuerich
Publication of MA53002A publication Critical patent/MA53002A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
MA053002A 2018-06-27 2019-06-25 Nouveaux composés de pyridine et de pyrazine en tant qu'inhibiteurs du récepteur cannabinoïde 2 MA53002A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18180137 2018-06-27

Publications (1)

Publication Number Publication Date
MA53002A true MA53002A (fr) 2021-05-05

Family

ID=62814868

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053002A MA53002A (fr) 2018-06-27 2019-06-25 Nouveaux composés de pyridine et de pyrazine en tant qu'inhibiteurs du récepteur cannabinoïde 2

Country Status (19)

Country Link
US (2) US12071420B2 (fr)
EP (1) EP3814329B1 (fr)
JP (1) JP7445610B2 (fr)
KR (1) KR102790077B1 (fr)
CN (2) CN112262132A (fr)
AU (2) AU2019294256B2 (fr)
BR (1) BR112020025013A2 (fr)
CA (1) CA3096777A1 (fr)
CL (1) CL2020003331A1 (fr)
CO (1) CO2020011855A2 (fr)
CR (1) CR20200643A (fr)
IL (1) IL279725B2 (fr)
MA (1) MA53002A (fr)
MX (1) MX2020012760A (fr)
PE (1) PE20210368A1 (fr)
PH (1) PH12020552152A1 (fr)
SG (1) SG11202009103WA (fr)
WO (1) WO2020002320A1 (fr)
ZA (1) ZA202005426B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006030671B4 (de) 2006-07-04 2008-10-02 Moeller Gmbh Schutzschalter-Kurzschließer-Kombination
TW201904943A (zh) 2017-06-20 2019-02-01 瑞士商赫孚孟拉羅股份公司 新穎吡啶衍生物
CN112638430B (zh) 2018-06-27 2023-05-16 豪夫迈·罗氏有限公司 放射性标记的大麻素受体2配体
CA3096777A1 (fr) 2018-06-27 2020-02-02 F. Hoffmann-La Roche Ag Nouveaux composes de pyridine et de pyrazine en tant qu'inhibiteurs du recepteur cannabinoide 2
EP3814337B1 (fr) 2018-06-27 2025-05-14 F. Hoffmann-La Roche AG Dérivés de pyridine et de pyrazine en tant qu'agonistes de cannabinoïde 2 préférentiels
JP7478672B2 (ja) 2018-06-27 2024-05-07 エフ． ホフマン－ラ ロシュ アーゲー カンナビノイド受容体２の阻害剤としての新規なアゼチジン置換ピリジン及びピラジン化合物
EP4423256A2 (fr) 2021-10-28 2024-09-04 Genentech, Inc. Systèmes et méthodes pour identifier des antigènes associés au cmh pour une intervention thérapeutique

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3775685B2 (ja) 1993-07-28 2006-05-17 ローン−プーラン・ロレ・リミテツド Ｐｄｅ▲ｉｖ▼およびｔｎｆ抑制剤としての化合物
GB0222493D0 (en) * 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
DE602005009500D1 (de) * 2004-02-24 2008-10-16 Glaxo Group Ltd Pyridinderivate und deren verwendung als modulatoren des cb2-rezeptors
GB0418047D0 (en) 2004-08-12 2004-09-15 Syngenta Participations Ag Fungicidal compositions
WO2006105217A2 (fr) 2005-03-31 2006-10-05 Schering Corporation Antagonistes du recepteur de la thrombine spirocyclique
FR2887550A1 (fr) 2005-06-24 2006-12-29 Sanofi Aventis Sa Derives de 1-benzylpyrazole-3-acetamide, leur preparation et leur application en therapeutique
DK1940821T3 (da) 2005-10-19 2013-06-10 Gruenenthal Gmbh Nye vanilloid-receptorligander og deres anvendelse til fremstilling af lægemidler.
CN101522644B (zh) * 2006-10-04 2013-04-24 霍夫曼-拉罗奇有限公司 作为cb2受体调节剂的吡嗪-2-羧酰胺衍生物
EP2311443A1 (fr) 2009-10-15 2011-04-20 Rheinische Friedrich-Wilhelms-Universität Composition pharmaceutique contenant des antagonistes de récepteur de cannabinoïde-2
US9321727B2 (en) 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
BR112014004310B8 (pt) 2011-08-25 2023-04-18 Merck Sharp & Dohme Composto de pirimidina inibidor da enzima fosfodiesterase 10, composição farmacêutica, uso de um composto
US9403808B2 (en) 2011-10-28 2016-08-02 Hoffmann-La Roche Inc. Pyrazine derivatives
WO2014071361A1 (fr) 2012-11-05 2014-05-08 Rubicon Genomics Marquage par code-barre d'acides nucléiques
SI2928882T1 (sl) 2012-12-07 2017-05-31 F. Hoffmann-La Roche Ag Pirazinski derivati kot agonisti receptorja CB2
HRP20171459T1 (hr) 2012-12-07 2017-11-03 F. Hoffmann - La Roche Ag Piridin-2-amidi korisni kao agonisti cb2
HRP20180672T1 (hr) 2012-12-07 2018-06-01 F. Hoffmann - La Roche Ag Novi derivati piridina
JP6426619B2 (ja) * 2012-12-07 2018-11-21 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｂ２アゴニストとして有用なピリジン−２−アミド
PE20151559A1 (es) 2013-03-26 2015-11-05 Hoffmann La Roche Nuevos derivados de piridina
CN106132958A (zh) 2014-04-04 2016-11-16 豪夫迈·罗氏有限公司 作为cb2激动剂的吡啶‑2‑酰胺类化合物
MX2016012690A (es) * 2014-04-04 2017-04-27 Hoffmann La Roche Piridin-2-carboxamidas 5,6-disustituidas como agonistas del receptor cannabinoide.
WO2016066534A1 (fr) 2014-10-27 2016-05-06 F. Hoffmann-La Roche Ag Ligands radiomarqués du récepteur cannabinoïde 2
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
SI3386951T1 (sl) 2015-12-09 2020-07-31 F. Hoffmann-La Roche Ag Fenilni derivati kot agonisti kanabinoidnega receptorja 2
IL269431B2 (en) 2017-03-23 2025-05-01 Univ Washington Methods for targeted nucleic acid sequence enrichment with applications to error corrected nucleic acid sequencing
TW201906818A (zh) 2017-05-31 2019-02-16 美商５１１製藥公司 新穎氘取代之正子發射斷層掃描（ｐｅｔ）顯影劑及其藥理應用
TW201904943A (zh) 2017-06-20 2019-02-01 瑞士商赫孚孟拉羅股份公司 新穎吡啶衍生物
KR20210010475A (ko) 2018-05-15 2021-01-27 룬드벡 라 졸라 리서치 센터 인코포레이티드 Magl 저해제
CN112638430B (zh) 2018-06-27 2023-05-16 豪夫迈·罗氏有限公司 放射性标记的大麻素受体2配体
EP3814337B1 (fr) 2018-06-27 2025-05-14 F. Hoffmann-La Roche AG Dérivés de pyridine et de pyrazine en tant qu'agonistes de cannabinoïde 2 préférentiels
CA3096777A1 (fr) 2018-06-27 2020-02-02 F. Hoffmann-La Roche Ag Nouveaux composes de pyridine et de pyrazine en tant qu'inhibiteurs du recepteur cannabinoide 2
JP7478672B2 (ja) 2018-06-27 2024-05-07 エフ． ホフマン－ラ ロシュ アーゲー カンナビノイド受容体２の阻害剤としての新規なアゼチジン置換ピリジン及びピラジン化合物
TWI687701B (zh) 2018-12-05 2020-03-11 宏碁股份有限公司 判斷電量狀態的方法及其電子裝置

Also Published As

Publication number Publication date
ZA202005426B (en) 2025-06-25
PH12020552152A1 (en) 2021-07-05
MX2020012760A (es) 2021-03-25
KR20210028202A (ko) 2021-03-11
AU2019294256A1 (en) 2020-09-24
CR20200643A (es) 2021-05-11
SG11202009103WA (en) 2020-10-29
KR102790077B1 (ko) 2025-04-03
US20240383872A1 (en) 2024-11-21
AU2024219640A1 (en) 2024-10-03
US12071420B2 (en) 2024-08-27
CN112262132A (zh) 2021-01-22
IL279725B1 (en) 2023-12-01
EP3814329C0 (fr) 2024-01-17
CA3096777A1 (fr) 2020-02-02
EP3814329B1 (fr) 2024-01-17
CO2020011855A2 (es) 2020-10-20
EP3814329A1 (fr) 2021-05-05
WO2020002320A1 (fr) 2020-01-02
IL279725A (en) 2021-03-01
AU2019294256B2 (en) 2024-06-20
JP2021529157A (ja) 2021-10-28
IL279725B2 (en) 2024-04-01
CL2020003331A1 (es) 2021-05-07
PE20210368A1 (es) 2021-02-26
CN119161323A (zh) 2024-12-20
BR112020025013A2 (pt) 2021-03-23
JP7445610B2 (ja) 2024-03-07
US20210115011A1 (en) 2021-04-22

Similar Documents

Publication Publication Date Title
MA53002A (fr) Nouveaux composés de pyridine et de pyrazine en tant qu'inhibiteurs du récepteur cannabinoïde 2
MA46196A (fr) Composés et compositions en tant qu'inhibiteurs de récepteurs de type toll endosomal
MA49013A (fr) Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2
MA53219A (fr) Nouveaux composés hétérocycliques en tant qu'inhibiteurs de monoacylglycérol lipase
MA43862A (fr) Spiroheptane salicylamides et composés associés en tant qu' inhibiteurs de rock
MA45189A (fr) Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2
MA54567A (fr) Pyridine et composés de pyridimine en tant qu'inhibiteurs de pi3k-gamma
MA53220A (fr) Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs de monoacylglycérol lipase
MA52486A (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA52754A (fr) Composés hétérocycliques tricycliques en tant qu'activateurs de sting
EP3755311A4 (fr) Indane-amines utiles en tant qu'antagonistes de pd-l1
MA49566A (fr) Carboxamides utilisés en tant qu'inhibiteurs des canaux sodiques
EP3856719A4 (fr) Composés en tant qu'antagonistes du récepteur 3 de l'histamine neuronale et leurs utilisations
EP3558974A4 (fr) Composés et méthodes pour la dégradation ciblée d'activateur du polypeptide homologue 2 de zeste
EP3807253A4 (fr) Composés cyano quinoléine amide utilisés en tant qu'inhibiteurs de her2 et procédés d'utilisation
MA51438A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
MA49374A (fr) Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine
EP3448522A4 (fr) Nouveaux composés d'imidazopyridine substitués en tant qu'inhibiteurs d'indoléamine 2,3-dioxygénase et/ou de tryptophane-2,3-dioxygénase
MA46878A (fr) Composés de benzodiazolium en tant qu'inhibiteurs d'enac
MA50439A (fr) Nouveaux dérivés de pyrazolo-pyrrolo-pyrimidine-dione utilisés en tant qu'inhibiteurs de p2x3
EP3728232A4 (fr) Nouveaux composés de quinolone utilisés en tant qu'inhibiteurs de l'interaction protéine-protéine du domaine bcl6 btb et/ou en tant qu'agents de dégradation de bcl6
EP3820530A4 (fr) Formulation de composés cannabinoïdes
EP3648773A4 (fr) Composés et procédés pour l'administration transmembranaire de molécules
MA53074A (fr) Dérivés d'oxadiazolopyridine à substitution hétérocyclyle utilisés en tant qu'inhibiteurs de la ghréline o-acyltransférase (goat)